Terms ending in 2039
Every in-force patent on Lifeedit, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,338,455 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | |
| US 11,926,843 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use In force · High confidence | LifeEDIT Therapeutics, Inc. | In force | High confidence | |
| US 12,188,018 | Polypeptides Useful for Gene Editing and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.